- Samsung Biologics posted consolidated revenue of KRW 1,660.2 billion and operating profit of KRW 728.8 billion in the third quarter of 2025.
- The company confirmed plans to complete the spin-off of its CDMO business by November 2025 and introduced its new ExellenS™ manufacturing framework.
Samsung Biologics, a contract development and manufacturing organisation (CDMO), has announced its financial results for the third quarter of fiscal year 2025, reporting consolidated revenue of KRW 1,660.2 billion and operating profit of KRW 728.8 billion. The growth was supported by full-scale operations at Plant 4 and consistent performance across all business units.
Standalone revenue reached KRW 1,257.5 billion, reflecting stable operations and efficient capacity utilisation. The company maintained its annual revenue growth guidance, citing steady client demand and project expansion.
During the quarter, Samsung Biologics continued to secure new development and manufacturing contracts with global pharmaceutical partners, bringing its cumulative contract volume to over USD 20 billion since its founding. The company reaffirmed that its planned spin-off to separate the CDMO business from its subsidiary remains on track for completion in November 2025.
Samsung Biologics also introduced ExellenS™, a new manufacturing framework designed to enhance standardisation, scalability, and speed across its global network. The framework integrates standardised designs, equipment, and processes to strengthen supply flexibility and accelerate delivery timelines.
“Our third quarter results reflect the solid foundation we have built through operational excellence and disciplined execution. We continue to prioritise standardisation and scalability across our global network under our ExellenS™ manufacturing framework, delivering speed, reliability, and predictable outcomes that our partners can count on.”
John Rim, CEO and President of Samsung Biologics
The company further advanced its environmental, social, and governance initiatives, including the establishment of a Product Carbon Footprint measurement system to manage emissions and its continued participation in the Sustainable Markets Initiative’s Health Systems Task Force. Samsung Biologics said it remains focused on reliability, innovation, and sustainable business practices to support its role as a trusted partner in global healthcare.
